Table 2.
Characteristics of participants in qualitative subset
| Characteristica | Low TFV-DP participants | High TFV-DP participants |
|---|---|---|
| Number of participants (n) | 15 | 7 |
| Age (median, IQR) | 17 (16–22) | 22 (19–25) |
| Site (n, %) | ||
| Urban | 7 (46.7%) | 3 (42.9%) |
| Rural | 8 (53.3%) | 4 (57.1%) |
| Method of study recruitment (n, %) | ||
| Home visit | 2 (13.3%) | 5 (71.4%) |
| Mobile site | 13 (86.7%) | 2 (28.6%) |
| Study arm | ||
| Control (PrEP pick-up only) | 4 (26.7%) | 2 (28.6%) |
| Adherence counseling (group) | 8 (53.3%) | 1 (14.3%) |
| Adherence counseling (one-on-one) | 3 (20%) | 4 (57.1%) |
| In school (n, %) | 10 (66.7%) | 3 (42.9%) |
| Household size (median, IQR) | 4 (4–7) | 4 (3–6) |
| Relation to household | ||
| Head of household | 0 (0%) | 1 (14.3%) |
| Family member e.g. daughter, sister, grandchild | 12 (80.0%) | 5 (71.4%) |
| Adopted / foster / stepchild | 1 (6.7%) | 0 (0%) |
| Relative of the household | 2 (13.3%) | 0 (0%) |
| Partner / wife | 0 (0%) | 1 (14.3%) |
| Taking contraception at baseline | 4 (26.7%) | 4 (57.1%) |
| Type of contraception used | ||
| Injectable contraceptives | 4 (100.0%) | 4 (100.0%) |
| Ever had sexual intercourse | ||
| At baseline | 8 (53.3%) | 4 (57.1%) |
| Between study months 12 – 24d | 9 (60.0%) | 4 (57.1%) |
| Received incentiveb in exchange for sexc | ||
| At baseline | 4 (26.7%) | 2 (28.6%) |
| Between study months 12 – 24d | 3 (20%) | 3 (42.9%) |
| Use condoms all or some of the timec | ||
| At baseline | 8 (53.0%) | 3 (42.9%) |
| Between study months 12 – 24d | 6 (40.0%) | 3 (42.9%) |
| PrEP disclosure since last interviewd | ||
| Yes | 10 (66.7%) | 7 (100%) |
| No | 4 (26.7%) | 0 (0.0%) |
| Refused to answer | 1 (6.7%) | 0 (0.0%) |
| Total reported PrEP disclosure eventsd | 19 | 22 |
| People disclosed to about PrEPd | ||
| Sex partner(s) | 3 (20.0%) | 5 (71.4%) |
| Parent/Guardian | 6 (40%) | 5 (71.4%) |
| Sibling | 4 (26.7%) | 4 (57.1%) |
| Friend(s) | 6 (40%) | 4 (57.1%) |
| Church/ Community leader | 0 (0.0%) | 2 (28.6%) |
| Reaction of person disclosed tod,e | ||
| Supportive | 15 (78.9%) | 22 (100.0%) |
| Not supportive | 2 (10.5%) | 0 (0.0%) |
| Neither supportive nor unsupportive | 1 (5.3%) | 0 (0.0%) |
| Prefer not to answer | 1 (5.3%) | 0 (0.0%) |
| Reported side effectsf | ||
| Study month 3 | 2 (15.4%) | 0 (0.0%) |
| Study month 12 | 3 (27.3%) | 2 (28.6%) |
| Study month 24 | 3 (20.0%) | 0 (0.0%%) |
| Ever any days that PrEP was not taken (self-reported)f | ||
| Study month 3 | 2 (15.4%) | 0 (0.0%) |
| Study month 12 | 2 (18.2%) | 2 (28.6%) |
| Study month 24 | 2 (13.3%) | 0 (0.0%) |
aAll responses represent survey data from study baseline unless otherwise specified
bIncentives include money, alcohol/drugs, clothes, mobile airtime, place to stay, rides, better marks at school, school fees, food, or anything else
cNot applicable amongst participants who reported never having sex or who skipped the question
dAll of these items were asked at the Month 24 study visit about the past 12 months, except for 1 participant who only had Month 12 behavioral survey data (asking about the past 9 months)
eCalculated as percentage across all reported disclosure events for Low TFV-DP v. High TFV-DP participants
fAsked whether experienced in the time period preceding the study visit (e.g., either in the past 3, 9, or 12 months for Month 3, Month 12, and Month 24 study visits, respectively). Missing data: Month 3 (n = 2 Low TFV-DP participants); Month 12 (n = 5 Low TFV-DP participants); Month 24 (n = 1 High TFV-DP participant)